Skip to main content
UniHealth

Doctor search

Ronald H Yanagihara, MD

Hematology/Oncology · Aiea

NPI 1366478240

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2

Offices

2 locations · Pali Momi Medical Center · 90 clinicians in this group

Looking this up.

Hospitals listed: Pali Momi Medical Center · Straub Clinic and Hospital. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Yanagihara’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence G47486 · Current

Licensed to practise in California · since 1982 · expires 2027-07-31 · University of Minnesota Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Pali Momi Medical CenterAiea, HIAcute Care Hospital · Proprietary · Has an emergency departmentPart of Hawaii Pacific Health, which runs 4 hospitalsPatients rate it 4 of 5 · 79% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.166, Oct 2024 – Sep 2025
  • Straub Clinic and HospitalHonolulu, HIAcute Care Hospital · Proprietary · Has an emergency departmentPart of Hawaii Pacific Health, which runs 4 hospitalsPatients rate it 4 of 5 · 75% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Postoperative respiratory failure rate: 16.47 (10.54 to 22.4) · 566 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.492, Oct 2024 – Sep 2025
See every measure and the patient survey for Pali Momi Medical Center

Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Pali Momi Medical Center
Clostridium Difficile (C.Diff)Infections0.166BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.84 (0 to 1.82) · 823 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.44 to 1.14)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths162.97 (113.96 to 211.98) · 41 casesNo differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths8.9 · 35 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.9 · 168 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.8 · 218 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.8 · 415 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 151 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.9 · 1,907 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.33 (0.12 to 0.54) · 3,322 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.24 (0.03 to 0.44) · 3,332 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.79 (0.59 to 4.99) · 834 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.53 (0 to 3.19) · 216 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.18 (0.61 to 3.75) · 741 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths5.46 (0 to 13.24) · 243 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.89 (1.03 to 8.74) · 219 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.96 (0.48 to 3.43) · 267 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.42 (0 to 1.16) · 2,957 casesNo differentJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.924No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.919No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.312No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.8 · 219 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.8 · 413 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits15.1 · 144 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits40.1 · 239 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-5.5 · 422 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.7 · 606 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.7 (4.5 to 9.6) · 157 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.6 (8.5 to 15.6) · 157 casesNo differentJan 2024 – Dec 2024
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 96 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.1 (9.2 to 16.3) · 578 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.9 to 1.5) · 387 casesNo differentJan 2024 – Dec 2024

What patients said (419 patients answered, 27% of those asked)

Patient survey stars by topic at Pali Momi Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines4
Discharge information4
Overall hospital rating4
Quietness4
Recommend hospital5
Share of patients giving the best answer at Pali Momi Medical Center
Room was "always" clean80%
Nurses "always" communicated well81%
Doctors "always" communicated well80%
Staff "always" explained65%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect85%
Patients who gave a rating of "9" or "10" (high)77%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect87%
"Always" quiet at night59%
"YES", patients would definitely recommend the hospital79%
Staff "always" explained possible side effects54%
Yes, staff "did" give patients information about possible symptoms89%
See every measure and the patient survey for Straub Clinic and Hospital

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Straub Clinic and Hospital
Postoperative respiratory failure rateComplications and deaths16.47 (10.54 to 22.4) · 566 casesWorseJul 2022 – Jun 2024
Clostridium Difficile (C.Diff)Infections0.492BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths2.02 (1.05 to 3) · 795 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.17 (0.85 to 1.48)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths157.42 (109.15 to 205.69) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2 · 70 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.7 · 35 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.2 · 140 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.3 · 234 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.6 · 314 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.5 · 157 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.2 · 2,463 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.36) · 3,593 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.23 (0.03 to 0.44) · 3,831 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.34 (2.2 to 6.48) · 1,181 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.61 (0.11 to 3.11) · 520 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths3.79 (2.28 to 5.3) · 1,005 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.85 (1.27 to 8.42) · 530 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.66 (0.18 to 3.15) · 197 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.39 (0 to 1.11) · 3,199 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.7 · 52 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.416No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.63No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.359No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.502No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.5 · 270 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.2 · 381 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits11.2 · 172 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.8 · 261 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits6.2 · 314 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.2 · 561 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.9 (3.4 to 7.1) · 256 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.1 (8.2 to 15) · 256 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.4 · 63 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11.4 · 68 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.7 · 63 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14.4 (11 to 18.8) · 1,140 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.3) · 630 casesNo differentJan 2024 – Dec 2024

What patients said (482 patients answered, 31% of those asked)

Patient survey stars by topic at Straub Clinic and Hospital
Cleanliness3
Nurse communication4
Doctor communication4
Communication about medicines4
Discharge information3
Overall hospital rating4
Quietness3
Recommend hospital4
Share of patients giving the best answer at Straub Clinic and Hospital
Room was "always" clean69%
Nurses "always" communicated well80%
Doctors "always" communicated well83%
Staff "always" explained63%
Yes, staff "did" give patients this information84%
Yes, staff "did" give patients information about help after discharge82%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully84%
Doctors "always" treated them with courtesy and respect88%
Patients who gave a rating of "9" or "10" (high)74%
Staff "always" explained new medications77%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital75%
Staff "always" explained possible side effects48%
Yes, staff "did" give patients information about possible symptoms85%

Original Medicare doctor bills

$11,992

Medicare paid this office $11,992 for 129 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)55$5,922$87
Short return visit (20+ min)47$2,869$57
New patient visit (30+ min)13$1,024$79

Who their Medicare patients are

129 Original Medicare patients in 2024. Average age 73 · Women 52% · Also on Medicaid 31% · Health risk score 1.84. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 65% · Cancer 60% · Diabetes 32% · Coronary heart disease 26% · COPD 26% · Chronic kidney disease 22% · Atrial fibrillation 20% · Heart failure 17% · Depression 11% · Stroke 10%.

The office billed $43,545, Medicare allowed $15,120 and paid $11,992; for 153 services of 6 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024129153731.84$43,545$11,992
20231314751.35$3,637$1,134
20223031722.11$9,040$1,299
2021141472751.90$99,248$39,233
2020137462751.92$83,889$30,340
2019150432762.10$79,483$26,991
2018184430751.83$76,403$26,054
2017244593741.64$105,101$34,511
2016241628731.88$112,904$36,563
20152266,236742.04$287,431$92,024
201443569,891751.75$3,536,729$1,264,211
201339099,860761.79$5,024,820$1,912,218

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2022: 1 service

Original Medicare services billed in 2022
Return visit (30+ min)14$253$17

2021: 6 services

Original Medicare services billed in 2021
Return visit (30+ min)34$12,966$106
Return visit (30+ min)43$12,720$80
Short return visit (20+ min)37$4,513$69
Short return visit (20+ min)57$4,454$49
New patient visit (45+ min)15$2,134$142
New patient visit (45+ min)17$1,966$116

2020: 6 services

Original Medicare services billed in 2020
Return visit (30+ min)44$12,030$63
Return visit (30+ min)19$6,472$91
New patient visit (45+ min)32$3,395$106
Short return visit (20+ min)53$3,030$38
Short return visit (20+ min)27$2,915$58
New patient visit (45+ min)14$1,728$123

2019: 5 services

Original Medicare services billed in 2019
Return visit (30+ min)53$9,506$61
Return visit (30+ min)21$8,029$87
Short return visit (20+ min)74$3,768$36
New patient visit (45+ min)23$2,371$103
Short return visit (20+ min)24$2,103$47

2018: 6 services

Original Medicare services billed in 2018
Return visit (30+ min)44$7,633$58
Short return visit (20+ min)98$5,268$36
Return visit (30+ min)21$4,535$87
New patient visit (45+ min)25$3,303$132
New patient visit (45+ min)26$2,577$99
Short return visit (20+ min)27$2,006$51

2017: 6 services

Original Medicare services billed in 2017
Return visit (30+ min)61$10,045$59
Short return visit (20+ min)121$6,700$36
Return visit (30+ min)20$5,368$83
New patient visit (45+ min)50$4,621$92
Short return visit (20+ min)51$3,907$49
New patient visit (45+ min)23$2,778$121

2016: 7 services

Original Medicare services billed in 2016
Return visit (30+ min)62$10,656$58
Short return visit (20+ min)123$7,123$37
New patient visit (45+ min)47$4,388$93
Short return visit (20+ min)50$3,973$52
New patient visit (45+ min)32$3,831$120
Return visit (30+ min)16$3,628$71
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes14$1,145$82

2015: 13 services

Original Medicare services billed in 2015
Return visit (30+ min)46$8,214$65
Short return visit (20+ min)92$5,568$40
New patient visit (45+ min)39$4,022$103
Short return visit (20+ min)48$3,230$51
Return visit (30+ min)25$2,814$78
New patient visit (30+ min)38$2,292$60
Administration of chemotherapy into vein, 1 hour or less11$1,536$140
New patient visit (45+ min)12$1,481$123
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less17$1,374$65
Infusion into a vein for hydration, 31-60 minutes15$862$48
Injection, dexamethasone sodium phosphate, 1 mg12$25None
Infusion, normal saline solution, 250 cc16$17None
Infusion, normal saline solution, sterile (500 ml = 1 unit)17$13None

2014: 43 services

Original Medicare services billed in 2014
Injection, rituximab, 100 mg13$247,209None
Injection, pegfilgrastim, 6 mg19$156,542None
Return visit (30+ min)174$54,229$93
Administration of chemotherapy into vein, 1 hour or less53$50,380$135
Short return visit (20+ min)265$28,911$62
Injection, zoledronic acid, 1 mg28$28,849None
Leuprolide acetate (for depot suspension), 7.5 mg16$21,084None
Injection, palonosetron hcl, 25 mcg30$19,985None
Injection, epoetin alfa, (for non-esrd use), 1000 units15$17,819None
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less49$15,834$30
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less50$13,863$70
Infusion into a vein for hydration, each additional hour77$8,116$15
New patient visit (60+ min)45$7,963$177
New patient visit (45+ min)51$6,981$137
Administration of chemotherapy into vein, each additional hour35$6,720$28
Infusion into a vein for hydration, 31-60 minutes38$6,376$58
Initial hospital care with moderate level of medical decision making at least 75 minutes28$5,151$178
Drawing of blood for a medical problem12$4,832$101
Administration of additional new drug or substance into vein, 1 hour or less18$4,092$62
Injection of additional new drug or substance into vein34$3,818$22
Injection of drug or substance under skin or into muscle34$3,432$25
Administration of additional new drug or substance into vein using push technique14$3,362$62
Biopsy of bone marrow23$3,356$146
Injection of drug or substance into vein18$2,571$57
Injection, paclitaxel, 30 mg12$1,713None
Return visit (30+ min)15$1,470$64
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle17$1,181$31
Irrigation of implanted venous access drug delivery device15$1,090$22
Short return visit (20+ min)22$1,040$42
Injection, carboplatin, 50 mg12$1,030None
New patient visit (30+ min)16$990$62
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour13$938$18
Office for the evaluation and management of established patient that may not require presence of healthcare professional24$782$20
Injection, dexamethasone sodium phosphate, 1 mg51$448None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service24$283$12
Injection, ranitidine hydrochloride, 25 mg13$179None
Injection, diphenhydramine hcl, up to 50 mg37$93None
Infusion, normal saline solution, sterile (500 ml = 1 unit)37$67None
Infusion, normal saline solution, 250 cc35$65None
Injection, heparin sodium, (heparin lock flush), per 10 units19$65None
5% dextrose/water (500 ml = 1 unit)20$56None
Injection, ondansetron hydrochloride, per 1 mg13$38None
5% dextrose/normal saline (500 ml = 1 unit)13$14None

2013: 35 services

Original Medicare services billed in 2013
Injection, rituximab, 100 mg18$274,142None
Injection, pegfilgrastim, 6 mg15$122,762None
Administration of chemotherapy into vein, 1 hour or less60$86,520$147
Return visit (30+ min)180$63,246$94
Injection, zoledronic acid (zometa), 1 mg25$49,180None
Injection, palonosetron hcl, 25 mcg43$41,766None
Short return visit (20+ min)283$40,633$64
Zoldedronic acid 1mg24$37,116$136
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less60$28,478$32
Injection, oxaliplatin, 0.5 mg12$27,222None
Administration of additional new drug or substance into vein, 1 hour or less35$17,851$73
Injection, epoetin alfa, (for non-esrd use), 1000 units14$16,865None
Administration of prolonged chemotherapy into vein15$16,624$147
Leuprolide acetate (for depot suspension), 7.5 mg11$15,529None
Administration of chemotherapy into vein, each additional hour42$12,410$31
Infusion into a vein for hydration, each additional hour87$11,413$15
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less36$10,904$76
New patient visit (45+ min)64$9,400$147
New patient visit (60+ min)50$9,219$184
Initial hospital care with moderate level of medical decision making at least 75 minutes41$7,663$170
Administration of additional new drug or substance into vein using push technique16$6,386$64
Injection of additional new drug or substance into vein50$6,232$23
Biopsy of bone marrow32$5,783$165
Injection of drug or substance under skin or into muscle45$5,281$26
Injection, irinotecan, 20 mg11$3,252None
Irrigation of implanted venous access drug delivery device28$2,856$25
Short return visit34$1,928$42
Injection, paclitaxel, 30 mg13$1,741None
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle13$1,478$33
Injection, carboplatin, 50 mg15$1,328None
Injection, fluorouracil, 500 mg15$1,242None
Injection, dexamethasone sodium phosphate, 1 mg61$555None
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service32$404$12
Injection, diphenhydramine hcl, up to 50 mg48$146None
Injection, ranitidine hydrochloride, 25 mg13$145None

Medicaid work

$4,575 in 2024

Medicaid paid $4,575 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
OFF/OP EST MAY X REQ PHY/QHP12$4,575
Medicaid work by year
202412112$4,575
202162215$2,301
2019122117$5,049
2018186216$7,249
See the largest Medicaid services in earlier years

2021

Largest Medicaid services in 2021
Return visit (30+ min)46$1,877
Short return visit (20+ min)16$424

2019

Largest Medicaid services in 2019
Return visit (30+ min)122$5,049

2018

Largest Medicaid services in 2018
Return visit (30+ min)142$6,066
Short return visit (20+ min)44$1,182

Drugs they prescribed that Part D paid

$284,739

Pharmacies billed $284,739 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 84) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.

67 generic and 17 brand-name prescriptions · $284,739 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Letrozole12$114$9

Year by year

Part D prescribing by year
202484370% (0)20%$284,739
2023722617% (12)None$82,188
20229033None56%$633,554
2021513977% (34)33%$2,352,558
2020533988% (42)None$2,369,591
201952210711% (59)29%$1,897,963
20185901297% (43)18%$1,240,325
20177351488% (60)None$788,923
20167481479% (68)20%$951,881
20155191405% (25)13%$349,536
201488414116% (138)16%$484,555
201390012019% (175)None$404,399

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2022: 2 drugs

Part D drugs prescribed in 2022
Tagrisso21$326,582$15,552
Dexamethasone13$165$13

2021: 12 drugs

Part D drugs prescribed in 2021
Tagrisso65$1,010,589$15,548
Revlimid19$323,039$17,002
Lenvima11$219,066$19,915
Lorbrena11$207,969$18,906
Alecensa17$186,781$10,987
Dexamethasone141$1,225$9
Ondansetron Odt44$535$12
Levothyroxine13$343$26
Hydrocodone-Acetaminophen14$227$16
Oxycodone11$221$20
Prednisone13$78$6
Furosemide16$37$2

2020: 11 drugs

Part D drugs prescribed in 2020
Tagrisso77$1,260,983$16,376
Lenvima19$373,627$19,665
Revlimid23$365,518$15,892
Lorbrena12$216,315$18,026
Alecensa12$98,778$8,231
Dexamethasone114$1,006$9
Ondansetron Odt48$624$13
Oxycodone20$436$22
Hydrocodone-Acetaminophen14$351$25
Letrozole19$345$18
Ondansetron13$138$11

2019: 13 drugs

Part D drugs prescribed in 2019
Tagrisso67$1,024,900$15,297
Ibrance22$277,361$12,607
Lenvima13$243,182$18,706
Exemestane12$1,478$123
Letrozole54$1,023$19
Dexamethasone55$727$13
Morphine Sulfate Er13$637$49
Hydroxyurea19$616$32
Oxycodone19$430$23
Anastrozole25$398$16
Levothyroxine11$233$21
Ondansetron24$198$8
Ondansetron Odt13$137$11

2018: 15 drugs

Part D drugs prescribed in 2018
Ibrance40$477,311$11,933
Lenvima11$214,198$19,473
Xtandi17$187,002$11,000
Tagrisso11$173,644$15,786
Exemestane16$15,208$950
Letrozole119$2,293$19
Tamoxifen Citrate19$946$50
Anastrozole44$736$17
Dexamethasone52$660$13
Hydrocodone-Acetaminophen11$370$34
Hydroxyurea14$342$24
Ondansetron26$207$8
Dicyclomine11$182$17
Ondansetron Odt16$146$9
Lorazepam20$43$2

2017: 16 drugs

Part D drugs prescribed in 2017
Ibrance46$526,410$11,444
Xtandi15$154,660$10,311
Exemestane23$17,267$751
Letrozole178$5,234$29
Anastrozole61$1,188$19
Tamoxifen Citrate18$954$53
Oxycodone21$626$30
Dexamethasone49$533$11
Ondansetron40$368$9
Hydroxyurea14$348$25
Levothyroxine13$277$21
Hydrocodone-Acetaminophen17$257$15
Lorazepam45$140$3
Loperamide12$139$12
Pantoprazole11$117$11
Sertraline13$83$6

2016: 19 drugs

Part D drugs prescribed in 2016
Revlimid23$216,328$9,406
Ibrance17$180,951$10,644
Sutent12$164,454$13,704
Gilotrif14$104,544$7,467
Exemestane29$18,342$632
Letrozole141$3,693$26
Anastrozole58$1,591$27
Tamoxifen Citrate18$793$44
Ondansetron27$688$25
Dexamethasone44$665$15
Hydrocodone-Acetaminophen13$516$40
Oxycodone21$500$24
Morphine Sulfate Er13$432$33
Potassium Chloride13$384$30
Lorazepam36$148$4
Metoprolol11$119$11
Pantoprazole13$94$7
Prednisone14$89$6
Sertraline13$60$5

2015: 9 drugs

Part D drugs prescribed in 2015
Exemestane42$20,695$493
Letrozole109$2,714$25
Anastrozole44$816$19
Tamoxifen Citrate15$726$48
Dexamethasone23$278$12
Ondansetron18$262$15
Prednisone12$87$7
Lorazepam22$72$3
Omeprazole11$41$4

2014: 28 drugs

Part D drugs prescribed in 2014
Xtandi18$147,026$8,168
Exjade14$52,574$3,755
Exemestane20$5,727$286
Oxycontin17$4,702$277
Letrozole119$2,473$21
Hydrocodone-Acetaminophen55$2,338$43
Morphine Sulfate Er19$2,077$109
Oxycodone33$1,905$58
Bicalutamide42$1,884$45
Hydroxyurea27$1,097$41
Venlafaxine11$759$69
Anastrozole38$749$20
Tamoxifen Citrate13$505$39
Levothyroxine34$430$13
Tamsulosin23$296$13
Dexamethasone20$222$11
Zolpidem24$178$7
Gabapentin19$126$7
Prednisone15$102$7
Alprazolam15$89$6
Metoclopramide19$84$4
Pantoprazole13$75$6
Omeprazole11$55$5
Lisinopril11$47$4
Citalopram Hbr11$46$4
Furosemide13$39$3
Simvastatin11$34$3
Diltiazem11$33$3

2013: 28 drugs

Part D drugs prescribed in 2013
Xtandi20$155,639$7,782
Revlimid13$107,201$8,246
Letrozole114$4,056$36
Exemestane18$3,364$187
Oxycodone47$2,497$53
Hydrocodone-Acetaminophen91$2,284$25
Bicalutamide17$1,296$76
Venlafaxine21$1,032$49
Anastrozole31$628$20
Lansoprazole12$564$47
Morphine Sulfate Er21$484$23
Tamoxifen Citrate20$458$23
Tamsulosin27$302$11
Dexamethasone36$289$8
Levothyroxine28$216$8
Spironolactone13$153$12
Omeprazole15$149$10
Pantoprazole18$138$8
Venlafaxine Hcl Er12$137$11
Warfarin11$129$12
Prednisone22$110$5
Furosemide32$107$3
Metoclopramide18$103$6
Lisinopril13$98$8
Alprazolam15$96$6
Gabapentin12$86$7
Zolpidem12$86$7
Lorazepam16$65$4

Money from drug and device companies

$366 in 2025

Industry payments by year
202545None$366
202412None$124
202356None$111
202222$200$325
2021817$5,748$6,125
2020517$3,444$3,603
201946$3,425$3,841

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Janssen BiotechRybrevant$172
2 payments
  • Meals for Rybrevant · 2025-12-16 · $146
  • Meals · 2025-11-20 · $26
Janssen Scientific AffairsRybrevant$102
1 payment
  • Meals for Rybrevant · 2025-09-25 · $102
Daiichi SankyoNone$74
1 payment
  • Meals · 2025-12-05 · $74
AstraZeneca Pharmaceuticals LPLynparza$18
1 payment
  • Meals for Lynparza · 2025-11-12 · $18
See all 5 published payments
Every published payment
Janssen BiotechMeals · 2025-12-16Rybrevant$146
Daiichi SankyoMeals · 2025-12-05None$74
Janssen BiotechMeals · 2025-11-20None$26
AstraZeneca Pharmaceuticals LPMeals · 2025-11-12Lynparza$18
Janssen Scientific AffairsMeals · 2025-09-25Rybrevant$102
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $124

Payments by company in 2024
AstraZeneca Pharmaceuticals LPEnhertu$124
2 payments
  • Meals for Enhertu · 2024-11-05 · $18
  • Meals · 2024-06-17 · $106

2023: $111

Payments by company in 2023
AstraZeneca Pharmaceuticals LPEnhertu$28
2 payments
  • Meals for Enhertu · 2023-09-27 · $16
  • Meals for Enhertu · 2023-06-29 · $13
Novartis PharmaceuticalsLutathera$25
1 payment
  • Meals for Lutathera · 2023-07-06 · $25
Astellas Pharma USXtandi$24
1 payment
  • Meals for Xtandi · 2023-03-07 · $24
EisaiLenvima$19
1 payment
  • Meals for Lenvima · 2023-08-21 · $19
ExelixisCabometyx$15
1 payment
  • Meals for Cabometyx · 2023-05-16 · $15

2022: $325

Payments by company in 2022
Novocure GmbHNone$200
1 payment
  • Honoraria · 2022-01-19 · $200
AstraZeneca Pharmaceuticals LPImfinzi$125
1 payment
  • Meals for Imfinzi · 2022-02-01 · $125

2021: $6,125

Payments by company in 2021
AstraZeneca Pharmaceuticals LPNone$2,398
1 payment
  • Consulting · 2021-10-31 · $2,398
G1 TherapeuticsCosela$1,500
1 payment
  • Honoraria for Cosela · 2021-08-20 · $1,500
BeiGeneNone$1,350
1 payment
  • Consulting · 2021-07-05 · $1,350
EMD SeronoTepmetko$500
1 payment
  • Consulting for Tepmetko · 2021-06-22 · $500
PfizerInlyta$218
10 payments
  • Education for Inlyta · 2021-11-16 · $8
  • Education for Inlyta · 2021-09-29 · $8
  • Education for Ibrance · 2021-09-28 · $13
  • Education for Inlyta · 2021-04-15 · $8
  • Education for Inlyta · 2021-04-15 · $124
  • Education for Inlyta · 2021-04-13 · $13
  • Education for Inlyta · 2021-04-13 · $8
  • Education for Inlyta · 2021-03-24 · $13
  • Education for Inlyta · 2021-01-13 · $8
  • Education for Inlyta · 2021-01-13 · $13
Blueprint MedicinesGavreto$131
1 payment
  • Meals for Gavreto · 2021-07-12 · $131
Janssen BiotechNone$18
1 payment
  • Meals · 2021-09-15 · $18
Gilead SciencesNone$12
1 payment
  • Education · 2021-06-01 · $12

2020: $3,603

Payments by company in 2020
Takeda Pharmaceuticals U.S.A.Alunbrig$2,147
3 payments
  • Consulting for Alunbrig · 2020-12-08 · $1,069
  • Consulting for Alunbrig · 2020-12-08 · $1,069
  • Education · 2020-10-15 · $10
Blueprint MedicinesNone$1,306
1 payment
  • Honoraria · 2020-09-09 · $1,306
PfizerLorbrena$126
11 payments
  • Education for Lorbrena · 2020-11-05 · $8
  • Education for Lorbrena · 2020-11-05 · $12
  • Education for Inlyta · 2020-10-08 · $13
  • Education for Inlyta · 2020-08-19 · $13
  • Education for Xalkori · 2020-02-13 · $14
  • Education for Lorbrena · 2020-02-13 · $11
  • Education for Braftovi · 2020-02-13 · $13
  • Education for Lorbrena · 2020-02-13 · $8
  • Education for Xalkori · 2020-02-10 · $14
  • Education for Lorbrena · 2020-02-10 · $11
  • Education for Lorbrena · 2020-02-10 · $8
Janssen PharmaceuticalsErleada$12
1 payment
  • Education for Erleada · 2020-02-19 · $12
ExelixisCabometyx$12
1 payment
  • Education for Cabometyx · 2020-01-15 · $12

2019: $3,841

Payments by company in 2019
AstraZeneca Pharmaceuticals LPTagrisso$3,554
2 payments
  • Consulting for Tagrisso · 2019-03-10 · $3,425
  • Meals · 2019-02-01 · $129
Merck Sharp & DohmeKeytruda$203
2 payments
  • Meals for Keytruda · 2019-07-12 · $125
  • Meals for Keytruda · 2019-02-01 · $78
ExelixisCabometyx$73
1 payment
  • Meals for Cabometyx · 2019-01-31 · $73
PfizerLorbrena$11
1 payment
  • Education for Lorbrena · 2019-11-18 · $11

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
ABBVIE INC. · Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (Abbv-399) in Subjects With Previously Treated C-Met+ Non-Small Cell Lung Cancer · 2021Their institution$49,441
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2022Their institution$15,000
AbbVie Inc. · 2020Their institution$12,300
CHIESI USA, INC. · Cusa-081-Hem-01 · 2020Their institution$6,500
CHIESI USA, INC. · Retavase · 2021Their institution$5,950
Genentech, Inc. · Ph III Open Label Stdy Atezo Vs Platinum Pemetrexed Gemcitabine for Pdl1 Chemo Naive Stg IV Nsclc · 2019Their institution$5,136
CHIESI USA, INC. · 2021Their institution$5,091

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
73.8 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1366478240
Licence
CA G47486California G47486: Current · expires 2027-07-31
Trained
University of Minnesota Medical School, 1974
Gender
Male
More record details
Sole proprietor
Yes
Medicaid ID
CA 00G474860
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
9360 No Name Uno #130, Gilroy, CA, 95020
NPI first listed
2006-06-23
NPI last updated
2013-07-28

This is when the NPI record was last certified, not a medical board exam.